RJA
AVXL icon

Raymond James & Associates’s Anavex Life Sciences AVXL Stock Holding History

Raymond James & Associates’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$66.1K Buy
+11,631
New +$67.1K ﹤0.01% 3825
2024
Q1 		– Sell
-12,129
Closed -$113K – 3924
2023
Q4 		$113K Sell
12,129
-500
-4% -$3.44K ﹤0.01% 3634
2023
Q3 		$82.7K Sell
12,629
-950
-7% -$7.56K ﹤0.01% 3630
2023
Q2 		$110K Buy
13,579
+384
+3% +$3.29K ﹤0.01% 3612
2023
Q1 		$113K Buy
+13,195
New +$132K ﹤0.01% 3625

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James & Associates's AVXL Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Anavex Life Sciences (AVXL) in Q3 2024: 11,631 shares worth $66.1K. The stake represents ﹤0.01% of the portfolio and ranks #3825 among its holdings. This is a return to the name: Raymond James & Associates previously reported a position in AVXL as recently as Q4 2023.

Raymond James & Associates first reported a position in AVXL in Q1 2023 and has held it in 5 quarters since. The position peaked at $113K in Q1 2023. 145 funds tracked by Wall St. Rank hold AVXL as of Q3 2024.

  • Raymond James & Associates held 11,631 shares of Anavex Life Sciences worth $66.1K as of Q3 2024.
  • Anavex Life Sciences was a new Raymond James & Associates position in Q3 2024.
  • Anavex Life Sciences made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3825 holding.
  • Raymond James & Associates first reported a position in Anavex Life Sciences in Q1 2023 and has held it in 5 quarters since.
  • Raymond James & Associates's Anavex Life Sciences position peaked at $113K in Q1 2023.
  • 145 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.